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Abstract Skeletal muscle hypertrophy is a result of
increased load, such as functional and stretch-overload.
Activation of satellite cells and proliferation, differentia-
tion and fusion are required for hypertrophy of overloaded
skeletal muscles. On the contrary, a dramatic loss of
skeletal muscle mass determines atrophy settings. The
epigenetic changes involved in gene regulation at DNA and
chromatin level are critical for the opposing phenomena,
muscle growth and atrophy. Physiological properties of
skeletal muscle tissue play a fundamental role in health and
disease since it is the most abundant tissue in mammals. In
fact, protein synthesis and degradation are finely modulated
to maintain an appropriate muscle mass. When the
molecular signaling is altered muscle wasting and weak-
ness occurred, and this happened in most common inher-
ited and acquired disorders such as muscular dystrophies,
cachexia, and age-related wasting. To date, there is no
accepted treatment to improve muscle size and strength,
and these conditions pose a considerable anxiety to patients
as well as to public health. Several molecules, including
Magic-F1, myostatin inhibitor, IGF, glucocorticoids and
microRNAs are currently investigated to interfere posi-
tively in the blueprint of skeletal muscle growth and
regeneration.
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Introduction
The basic contractile unit of skeletal muscle is the muscle
fiber; thousands of muscle fibers form together an individ-
ual skeletal muscle. Muscle fibers are limited by a plasma
membrane (sarcolemma) surrounded by a basal lamina, and
outside of this, a connective tissue composed by scarce
ECM (extra cellular matrix) proteins, capillaries and nerve
terminals (Buckingham 2001). Muscular hypertrophy and
atrophy are two opposite and mechanistically linked phe-
nomena regulating muscle cell size, finally determined
throughout a balance between new protein accumulation
and degradation of pre-existing proteins (Sandri 2008). In
response to exogenous stimuli or to biological factors such
as age or nutrition, the muscle is able to adapt by increasing
the size and amount of contractile proteins (Fig. 1). This
leads to increase in fiber size and their consequent force
production. Muscle remodeling occurs throughout the entire
life although at different rate considering the developmental
stages. During embryo formation and childhood, upregu-
lation of protein synthesis is accompanied by a cellular
turnover, in which satellite cells incorporate into new
muscle growing fibers. In adult muscle, cellular turnover is
strongly reduced and the physiological conditions leading
to muscle growth are basically determined by increasing
synthesis and downregulating protein turnover (Schiaffino
et al. 2007). Basically, two different forms of hypertrophy
exist: sarcoplasmic and myofibrillar; the first is character-
ized by an increase in the sarcoplasmic volume with no
accompanying increase in muscular strength. During myo-
fibrillar hypertrophy, the myofibrils increase in number and
add muscular strength as well as a small increase in muscle
size. Sarcoplasmic hypertrophy is characteristic of body-
builder muscles while myofibrillar hypertrophy is charac-
teristic of weightlifters. In stark contrast, muscle atrophy
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also called muscle wasting is the result of contractile protein
loss with a reduction in fibers cross sectional area and
consequently in muscle growth. At the molecular level,
signals controlling muscle growth or atrophy are different
but finely interconnected (Fig. 1), and the biochemical
pathways convert on a common set of molecules regulating
protein synthesis or breakdown (Sartorelli and Fulco 2004).
Nonetheless, these two processes basically hold the key
to understanding the mechanism involved in the regulation
of skeletal muscle growth. Recently, stem cell therapy
approaches are rapidly developing to counteract muscle
degeneration mainly by exogenous cell delivery or endog-
enous activation of muscle progenitors (Sampaolesi et al.
2005). Those techniques also result in muscle mass increase
providing new, functional fibers to the damaged muscle
(Rudnicki et al. 2008). In this review, molecular mecha-
nisms regulating muscle growth will be elucidated, briefly
describing the major determinants and further considering
the role of satellite cells in promoting muscular hypertro-
phy. Finally we also take into account the effect of exoge-
nous stem cell delivery and endogenous stem cell activation
on skeletal muscle mass and architecture.
Magic-F1 and muscle remodeling
Magic-F1, which name stays for cMet Activating Geneti-
cally Improved Chimeric Factor-1, is a recombinant protein
containing a tandem repetition of the Hepatocyte Growth
Factor (HGF) domains mainly involved in the cMet acti-
vation (Cassano et al. 2008). While during development
HGF/cMet signaling mediates homing of progenitors cells,
in adulthood is responsible of activation and early prolif-
eration phase of satellite cells. Although satellite cells are a
functionally heterogeneous population, it is widely
believed that those cells are the committed stem cells of
adult skeletal muscle tissues. Then, the signal is shut off to
allow myogenic differentiation, since HGF promotes pro-
liferation by inhibiting the differentiation program. By
contrast, Magic-F1 displays a selective pattern of biologi-
cal activities qualitatively different from its native factor.
Magic-F1 supports Protein kinase B (PKB/Akt) but not
Mitogen Activated Protein Kinase (MAPK) phosphoryla-
tion, thereby inhibiting proliferation of skeletal muscle
progenitors though retaining the ability to stimulate the
anti-apoptotic cascade. Magic-F1 protects myogenic pre-
cursors against apoptosis, thus increasing their fusion
ability and enhancing muscular differentiation. Myogenic
cell line C2C12 expressing the recombinant factor showed
a faster differentiation compared with mock, together with
an early upregulation of master genes such as MyoD and
Myf5. In vivo, muscle hypertrophy and cell survival are
elicited following Magic-F1 expression; transgenic mice
expressing the recombinant protein in a muscle specific
fashion show muscle hypertrophy along with faster
regeneration after injury and increased capillary formation.
Together with that, a better running performance and
muscular strength was observed in transgenic mice.
Crossing of Magic-F1 transgenic mice (Fig. 1) with
a-sarcoglycan knock-out mice –a mouse model of muscu-
lar dystrophy– or adenovirus-mediated Magic-F1 gene
delivery resulted in amelioration of the dystrophic pheno-
type as measured by both anatomical/histological analysis
and functional tests. Because of these features, Magic-F1
represents a novel factor able to dissociate the mitogenic
effect of HGF from its anti-apoptic properties and a good
candidate in counteracting wasting and degeneration in
muscular diseases such as muscular dystrophy. Given its
small size, it could be used as an adjuvant transgene to
improve homing and efficacy of gene and cell therapy
protocol (Fig. 1).
IGF-1 pathways
Insulin Growth Factor-1 (IGF-1) is among the best char-
acterized muscle growth promoting factors, produced
mainly in the liver under the control of the Growth Hor-
mone (GH) but its expression is located also in the skeletal
muscle, suggesting a paracrine/autocrine role of IGF-1 in
positively regulating muscle growth. Different isoforms of
IGF-1 exist thanks to different RNA spliced variants.
Human skeletal muscle has been found to express at least
two isoforms (Hameed et al. 2004). These are IGF-1Ea,
which is the liver type or systemic form and IGF-1Ec, also
called Mecano Growth Factor (MGF), an autocrine/para-
crine form that is particularly interesting as it is expressed
in response to mechanical stimuli and cellular damage.
Fig. 1 Muscle remodeling is a complex interplay among many key
factors, controlling both protein synthesis and satellite cells activa-
tion. As a final result, fiber size and nuclear content can be increased
(hypertrophy, left panel) or strongly reduced (atrophy, right panel)
Molecules positively (left arrows) and negatively (right arrows)
affecting fiber size are indicated
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Increased muscle loading results in augmented expression
of the IGF-1 encoding gene both in humans and animal
models (DeVol et al. 1990; Bamman et al. 2001). MGF
expression peaks earlier than IGF-1Ea and after damage or
mechanical stress is produced as a pulse lasting only
2 days, then replaced by a longerlasting expression of IGF-
1Ea (Haddad and Adams 2002; Hill and Goldspink 2003;
Haddad and Adams 2004).
The latter factor is likely to be involved in maintaining
protein synthesis to complete the muscle trophism, fur-
thermore IGF1Ea can promote both proliferation and dif-
ferentiation of satellite cells (Allen and Boxhorn 1989;
Doumit et al. 1996; Adi et al. 2002). IGF-1Ea induced
muscle hypertrophy is accompanied by an increase in DNA
content, centronucleated fibers and upregulation of differ-
ent myosin isoforms; supporting the involvement of satel-
lite cells in IGF-1 signals (Adams and McCue 1998;
Fiorotto et al. 2003). Muscle specific overexpression of
IGF-1Ea in transgenic mice results in muscle hypertrophy
and increased regeneration during senescence, together
with a corresponding increase in physiological muscle
strength (Coleman et al. 1995; Musaro et al. 2001). IGF-1
isoforms act through direct interaction with their own
receptor IGFR-1, a tyrosin-kinase leading to the final
activation of the AKT by the generation of phosphatidyl-
inositol-3,4,5-triphosphates (PIP3). Phosphatidylinositol-3
Kinase (PI3Kinase) and the phosphatases PTEN and SHIP2
represent the first checkpoint of this pathway by inversely
regulating the formation of PIP3, which recruits AKT on
the plasma membrane allowing the direct phosphorylation
by PDK1 and the mTOR-Rictor complex. In mammals,
there are three different AKT genes: AKT1 (PKBa), AKT2
(PKBb) and AKT 3 (PKBc) involved in different functions;
in skeletal muscle AKT1 seems to be the responsible for
mediating the muscle growth and protein upregulation
signals (Yang et al. 2004). Two major AKT downstream
molecules relevant for muscle remodeling are the mecha-
nistic target of rapamycin (mTOR), activated by AKT, and
glycogen synthase kinase 3b (GSK3b), inhibited by AKT.
Forkhead transcription factors (FoxOs) represent the third
mediator of this pathway, crosslinking the synthesis protein
machinery with the muscle atrophy program. Basically
GSK3b blocks protein translation by inhibiting the eIF2B
factor, so probably GSK3b participates in muscle growth
processes in a mTOR-independent fashion, also if it is still
debated if its inhibition is sufficient to induce per se muscle
hypertrophy (Hardt and Sadoshima 2002). mTOR is
selectively blocked by the immunosuppressant rapamycin
and this complex is composed by two distinct elements:
mTORC1, which contains Raptor, is rapamycin sensitive
and acts on S6 K and 4EBP1 signaling. It is still unclear if
S6 K is activated only by mTORC1 or if other molecules
could trigger it but might be that, before the final activation
by mTORC1, S6 K need to be primed by direct phos-
phorylation of PDK1 (Saitoh et al. 2002; Hannan et al.
2003). In addition, mTORC1 targets directly the inhibition
of 4EBP-1 (called also PHAS-1), which is a negative
regulator of the eIF-4E initiation factor; this system is
thought to be the main route through which the mTOR
complex induces protein synthesis and muscle growth.
Thus, mTORC1-mediated inhibition of 4EBP1 together
with the inhibition of GSK3b results in the activation of
eIF-4E and eIF-2B, respectively, with subsequent increase
in protein synthesis and muscle mass. The mTORC2
complex, which contains Rictor, is more involved in the
atrophic pathway by regulating in turn the AKT-FoxOs
complex. AKT plays a key role in modulating the atrophic
pathway by cytoplasmic retention and inactivation of FoxO
proteins, mediated by the mTORC2 complex (Tran et al.
2003; Sandri et al. 2004) (Fig. 2). FoxO proteins are very
conserved transcription factors originally discovered as
genes overexpressed in rabdomyosarcoma and tumorigenic
processes (Greer and Brunet 2005). In vitro, C2C12 cells
overxpressing FoxOs showed a strong inhibition of the
differentiative events, by contrast silencing of FoxOs
results in an enhanced differentiation associated with
myosin upregulation (Hribal et al. 2003). In vivo, consti-
tutive activation of FoxOs protein causes a dramatic atro-
phy of myotubes and mature muscle fibers. In muscle, three
different isoforms of FoxO proteins exist, namely called
FoxO1, FoxO3a and FoxO4. During muscle atrophy FoxOs
expression level are increased and reduced AKT activity
induces dephosphorilation of these factors and their con-
sequent activation. Moreover, FoxOs can in turn upregulate
4EBP1 and inhibit Raptor and mTOR, providing another
mechanism of skeletal muscle atrophy (Southgate et al.
2007). Because FoxOs play a key role in activating the
atrophic program thanks to the atrogenes Muscle Ring
Fig. 2 AKT plays a dual role in muscle remodeling. At molecular
level, AKT represents the main crosstalk between hypertrophic and
atrophic pathway. Positive (left side of the panel) and negative (right
side of the panel) regulators of its activity are indicated. Following
activation, AKT acts by either activating or blocking molecular
targets controlling cell metabolism and growth
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Finger 1 (MURF1) and muscle atrophy F-box (MAFbx,
also known as Atrogin-1), inactivation of these pathways
finally prevent atrophic events. Transgenic mice expressing
FoxOs in a muscle specific way show reduced body weight
and dry mass together with smaller fiber size (Kamei et al.
2004). A second atrophic FoxO-independent system
downstream of AKT cascade has been recently discovered
by the isolation of a group of genes sensitive to dexameth-
asone treatment and inversely regulated by IGF-1 treatment,
pointing out the existence of multiple checkpoints of atro-
phy signaling downstream of PI3 K/AKT cascade (Latres
et al. 2005). The crosstalk network between protein degra-
dation and muscle growth is complicated and involved not
only AKT but also downstream proteins such FoxOs and a
fine tuned balance of these pathways is needed to guarantee
a correct muscle mass (Fig. 2).
Atrophy and atrogenes
Skeletal muscle atrophy is characterized by a decrease in
the size of pre-existing muscle fibers and is observed in
many physiological and pathological conditions such as
microgravity, critical illness, HIV, cancer cachexia and
aging (Sever et al. 1996; Miro et al. 1997; Baracos 2001;
Mitch and Price 2001; Singh et al. 2001; Adams et al. 2002,
2003; Di Giovanni et al. 2004; Price et al. 2006). It has been
demonstrated that muscle atrophy is regulated by the cros-
stalking of well known pathways such as the calpain sys-
tem, the lysosomal and the ubiquitin–proteasome pathways.
All these systems are responsible for the proteolysis of
structural muscle proteins, leading to muscle wasting
(Voisin et al. 1996; Huang and Forsberg 1998; Lecker et al.
1999). A major contribution in understanding the process of
atrophy came from the pioneeristic study focused on the
molecular behavior of key molecules such as MAFbx and
MURF1 (Bodine et al. 2001; Gomes et al. 2001). Using
differential display and complementary cDNA microarray
approaches coming from different animal models of atro-
phy such as diabetes, cancer cachexia, denervation, these
two genes were identified to be overexpressed compared to
control animals. These two genes correspond to ubiquitin-
protein ligases expressed solely in skeletal and cardiac
muscle that mediate the processes of muscle remodeling
and increase proteolysis of disuse atrophy. For instance,
MURF1 was firstly identified as the ubiquitin-ligase
responsible for the direct binding and degradation of titin, a
huge myofibrillar protein, and myosin heavy chain
(McElhinny et al. 2002; Clarke et al. 2007). Further confirm
of the functional role of these atrogenes came from the
experiments performed on MAFbx-/- and MURF1-/-
transgenic mice, refractory to muscle-loss phenomena
induced by denervation. Importantly, during normal muscle
homeostasis there are no evidences of muscle alteration in
the transgenic mice, suggesting that those genes do not play
a key role in physiological processes. These finding uncover
that atrophy is not simply a ‘‘loss of hypertrophy’’ but a real
active process controlled by specific signals and biochem-
ical pathways. Nonetheless, muscle atrophy program is
linked with hypertrophic pathways. As mentioned in the
previous section, IGF-1Ea activation blocks through the
AKT-FoxO complex the accumulation of MAFbx tran-
scripts and prevents proteolysis events in dexamethasone-
induced atrophy animal model (Sacheck et al. 2004).
Animal models of muscular atrophy treated with intra-
muscular injection of IGF-1 show no increase in MAFbx
and MURF1 mRNA and the benefit observed in treated
animals is mostly due to the dephosphorylation and reduced
activation of FoxO1 and FoxO3a. Moreover, FoxOs can
downregulate both Raptor and mTOR and upregulate
directly 4EBP1. These results clearly indicate that the
IGF-1-AKT pathway prevents atrophy operating through
the FoxO proteins (Sandri et al. 2004; Stitt et al. 2004;
Southgate et al. 2005). In certain pathological conditions,
nuclear Factor jB (NF-jB) represents another factor
involved in muscle wasting by mediating the effects of
Tumor Necrosis Factor a (TNFa) and Interferon c (IFN-c),
however, NF-jB seems not linked to MAFbx and MURF1
signaling, since NF-jB overexpression doesn’t interfere
with MAFbx expression (Li et al. 2003; Sandri et al. 2004;
Southgate et al. 2007). In vitro studies on C2C12 system
suggest that blockade of NF-jB avoids protein loss content
and postulate that probably the TNFa-induced inhibition of
myogenesis has to be addressed to a failed recruitment of
satellite cells in the muscle fibers (Guttridge et al. 2000; Li
and Reid 2001). NF-jB could also act by inducing the
degradation of the master gene MyoD, raising the general
conclusion that different mediators of muscle atrophy might
operate at different stages. The crosstalk of these mediators
ensures a fully and complete atrophy program (Guttridge
et al. 2000). Trigging signal of atrophy mediated by TNFa
may be represented also by p38, able to upregulate MAFbx
expression but not MURF1, and acting through an NF-jB
independent pathway. By reverse, pharmacological inhibi-
tors of p38 block the atrophic pathway and stabilize the
atrogin-1 levels (Li et al. 2005).
Myostatin
Some cattle breeds such as the Belgian Blue display an
hypertrophic phenotype with a great increase in muscle
mass, such phenotype has been correlated with mutation
occurring in the myostatin gene, also named growth and
differentiation factor 8 (GDF8) (Charlier et al. 1995). In
2004, Schuelke et al. (2004) described for the first time a
mutation of the myostatin gene in humans correlating with
an enlargement of the skeletal muscle apparatus. So
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myostatin, a member of the TGFb superfamily, is consid-
ered one of the powerful negative regulators of muscle
growth, and in mice knockout of myostatin gene leads to a
terrific increase of muscle growth (McPherron et al. 1997).
In mice, myostatin is predominantly expressed in skeletal
muscle, both at 9.5 days post coitum (dpc) and in adult-
hood; the transcript is located preferentially in red than in
white muscles suggesting that myostatin could be involved
in the growth balance between fast and slow muscles
(McPherron et al. 1997; Roberts and Goetz 2001). Like all
TGFb members, myostatin exerts its activity through the
tyrosin-kinase receptors type I and type II, and several
studies reveal that probably the Activin Receptor IIB
mediates the myostatin action (Lee and McPherron 2001).
Following tetramerization of the receptor complex, the
signal is relayed into the cytoplasm thanks to SMAD
protein phosphorylation (Seuntjens et al. 2009); the regu-
latory SMAD 2 and 3 binds to SMAD4 and translocate into
the nucleus to modify gene expression. In addition, the
inhibitory SMAD7, which expression is induced by myo-
statin, represents a negative feedback loop mechanism by
preventing the formation of a correct SMAD complex and
blocking myostatin-induced cascade (Massague and Chen
2000; Ebisawa et al. 2001; Zhu et al. 2004). Other proteins
are able to interfere with myostatin activity by direct
binding, such as the growth and differentiation factor-
associated protein-1 (GASP-1), the follistatin related gene
(FLRG) or the follistatin, all these proteins basically inhibit
muscle atrophy when bound to different myostatin iso-
forms (mature or immature peptide) (Nakamura et al. 1990;
Iemura et al. 1998; Amthor et al. 2002; Hill et al. 2003).
Transgenic mice expressing the human isoform of follist-
atin in muscles display a huge increase in muscle mass
comparable to the one observed in myostatin null mice
(Lee and McPherron 2001). 6 months old myostatin-null
mice show a striking 40% increase of muscle mass com-
pared both to heterozygous and wild type counterpart with
a 2- 3-fold increase in muscle weight. On the opposite,
transgenic male mice overexpressing myostatin show a
20% decrease in the cross sectional area with a reduced
number of nuclei per myofiber. Surprisingly, transgenic
female mice are not affected by myostatin overexpression
(Reisz-Porszasz et al. 2003). Overall, a mild downregula-
tion of myostatin expression is sufficient to induce muscle
hypertrophy but not hyperplasia whereas total myostatin
suppression does. The myostatin expression is regulated by
many factors as demonstrated by the presence of E-boxes
(MyoD binding sites), MEF2 binding sites, GREs and
androgen response elements (ARE), suggesting that its
activity is required also to control important myogenic
events such as myoblast differentiation and proliferation
(Ma et al. 2001; Spiller et al. 2002; Crisa et al. 2003;
Salerno et al. 2004). In vitro studies on C2C12 demonstrate
that myostatin treatment could control cell cycle progres-
sion and inhibit myoblast proliferation by upregulating the
p21 expression and decreasing the phosphorylation of ret-
inoblastoma 1 protein (pRb); nonetheless myostatin treat-
ment perturbs also the myogenic differentiation events by
decreasing MyoD, Myf5 and myogenin levels whereas
myostatin silencing leads to a considerable fusion index
increment (Langley et al. 2002; Rios et al. 2002; Joulia
et al. 2003). Thanks to the ability of modulating muscle
mass, myostatin expression could be translated in a thera-
peutic view in order to improve muscle function in several
pathologies. Different experimental strategies have been
adopted and most of them used the mdx mice as disease
model, containing a nonsense mutation in the dystrophin
gene and representing a genetic orthologue of Duchenne
and Becker muscular dystrophy with progressive muscle
wasting, fiber necrosis and continuous cycles of regenera-
tion/degeneration occurring (Nowak and Davies 2004;
Coulton et al. 1988a, b). Double crossing of myostatin-null
with mdx mice or systemic injection of blocking antibodies
in the dystrophic recipient results in an increased body
weight and muscle mass and decreased degeneration rate
leading to an attenuation of the dystrophic phenotype
(Bogdanovich et al. 2002, 2005 Wagner et al. 2002). Sur-
prisingly, myostatin blockade is not able to rescue the
phenotype in another model of muscular dystrophy lacking
laminina2 expression, the dyw/dyw mice, claiming that
probably myostatin targeting cannot be considered a gen-
eral treatment for all muscular dystrophies (Li, Shelton
et al. 2005). Greatly controversial is the influence of
myostatin on satellite cells behavior during adulthood,
since few years ago all the studies report that myostatin
inhibition positively regulates satellite cells activation. In
myostatin-null mice, twofold activation of satellite cells,
faster regeneration rate together with a decrease in the
inflammatory cells recruitment, fibrosis and fatty infiltra-
tion in the injured sites was reported and compared to the
cardiotoxin-treated wild type counterpart (Wehling et al.
2000; McCroskery et al. 2003, 2005; Wagner et al. 2005).
More recently, these conclusions were strongly criticized
by the group of Partridge showing that muscle hypertrophy
driven by myostatin blockade not involves satellite cells.
According to their results myostatin inhibition doesn’t
interfere with satellite cells proliferation and hypertrophic
fiber contains no more myonuclei or new satellite cells.
Moreover, they report a faint expression of myostatin
receptor by satellite cell with any apparent contribution of
myonuclei from satellite cells in the hypertrophic muscle of
dystrophic mice treated with myostatin neutralizing anti-
bodies (Amthor et al. 2006). It is clearly important, before
to consider further clinical trials using myostatin blockade,
to elucidate its action on satellite cells and especially on the
determination of adult muscle stem cells that later
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contribute on muscle homeostasis. If our knowledge about
myostatin involvement in muscle size and regeneration is
continuously growing, less is known about its effect on
adipose tissue. In vitro data show that 10T/2 cells treated
with azacytidine and recombinant myostatin upregulate the
expression of early and late adipogenic markers, and this is
consistent with the observation in myostatin-null mice,
where serum leptin levels were strongly decreased with a
age-dependent reduction of the total fat body mass, up to
70% in 32 weeks old mice (McPherron and Lee 2002;
Artaza et al. 2005).
Glucocorticoid
A brief note just to mention that glucocorticoid level are
shown to be elevated in muscle wasting conditions and that
at molecular level glucocorticoid treatment succeed to
upregulate the expression of atrogenes both in vitro and in
vivo. At variant, treatment with glucocorticoid receptor
antagonists mild muscle loss in some pathological condi-
tions. Still debated is the mechanism through which these
compounds act intracellularly and which would be the
pathway targeted. No direct regulation of atrogenes
expression was described; neither glucocorticoid respon-
sive elements (GRE) were identified on atrogenes pro-
moters. Recently, some reports show a downregulation of
IGF-1 and upregulation of myostatin secretion following
glucocorticoid treatment, also if loss and gain of function
experiments on glucocorticoid receptor needs to be per-
formed in order to better elucidate their direct role in
muscle growth. (Sacheck et al. 2004; Sandri et al. 2004;
Schakman et al. 2008).
Dystrophin-glycoprotein complex (DGC)
It sounds a bit weird to discuss about DGC in controlling
muscle size since 7 years ago it was thought to play a pure
structural role by anchoring the cellular cytoskeleton to the
sarcomembrane. The members of this complex include at
least 12 different gene products, dystrophin, dystroglycans,
four sarcoglycans (possibly 5 or 6), sarcospan, syntrophins,
nitric oxide synthetase (nNOS) and dystrobrevin. They are
membrane-spanning subunits, such as b-dystroglycan and
sarcoglycans, as well as strictly intracellular and extracel-
lular components, such as syntrophins, dystrobrevin and
a-dystroglycan. Muscle contraction in both heart and
skeletal muscle results in cellular deformation and short-
ening. Throughout this process, the contractile machinery
inside the myofibers must remain intimately connected
with the membrane and extracellular matrix, thanks to the
final binding of a-dystroglican, on the muscle membrane,
with laminin-2 located in the extracellular matrix. Without this
association, movement would be improperly transmitted
and myocytes would risk damage to their membranes. One
function of the dystrophin glycoprotein complex (DGC) is
to provide a strong mechanical link from the intracellular
cytoskeleton to the extracellular matrix (Lapidos et al.
2004). Considerable work has focused on identifying the
members of this complex and delineating the functions of
the individual parts and the complex as a whole. First data
concerning a possible role of this complex in signaling
pathways was reported by the group of Rando in 2002,
showing that disruption of laminin-2 binding to the dys-
troglican complex has been able to inhibit AKT activation,
one of the master regulator of muscle hypertrophy
(Langenbach and Rando 2002). Since laminin is able to
stimulate integrin receptors it was unclear whether the
molecular mechanisms of AKT inhibition would be
accounted by DGC complex or indirectly by the integrin
system. A possible solution came from the studies per-
formed by Acharyya et al (2005) on dystrophin expression
in cachectic tumor-induced animal models. In atrophic
conditions, the authors observed a strong perturbation of
the myofibrillar component in skeletal muscle connecting
the cachexia tumor-induced with a loss of DGC integrity
and the upregulation of muscle wasting became more
stressed when the tumors were injected in the mdx animal
model, lacking dystrophin expression. If the latter conclu-
sion could be not surprising because mdx muscles are
damaged per se, the author went deeper in the system by
analyzing muscle wasting using an animal model over-
expressing dystrophin and they observed that in atrophy
conditions the muscle loss was less pronounced compared
to both wt and mdx mice concluding that dystrophin
expression could help to counteract muscle wasting events.
Nonetheless, a strong downregulation of atrogenes such as
MAFbx and MURF1 was observed in dystrophin trans-
genic compared both to wt and mdx mice, let them possible
to speculate that if AKT play a key role in downregulating
MAFbx and MURF1 and its activity is perturbated by DGC
complex, this pathway is the one regulated by dystrophin
and its binding proteins. Naturally, direct evidence is
missing and the authors raise the possibility of other
mechanisms involved including an AKT-independent
downregulation of atrogenes. In fact, new reports claim
that nNOS, disregulated during muscular dystrophy, targets
directly the upregulation of FoxOs transcription factor
representing a direct link between dystrophin and muscle
atrophy (Suzuki et al. 2007).
Satellite cells and muscle remodeling
Satellite cells can be identified by their position beneath the
basal lamina of muscle, closely juxtaposed to muscle fibers
(Mauro 1961). They are considered the main progenitors of
adult skeletal muscle and present several stem cell
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properties (Zammit and Beauchamp 2001; Dhawan and
Rando 2005; Zammit et al. 2006). In adult healthy muscle
fibers, the percentage of satellite cells is very low around
2,5–6% of fiber nuclei, but once activated they can gen-
erate large numbers of new myotubes, within 3–4 days
after severe injury (Whalen et al. 1990). Under normal
conditions they are quiescent and can be recognized not
only by the position, but also by the expression of char-
acteristic markers. One of the most important gene,
expressed in the vast majority of quiescent satellite cells
and in fetal progenitors of the myogenic lineage, is the
paired-box transcription factor Pax7 (Beauchamp et al.
2000; Reimann et al. 2004; Zammit et al. 2006). The
addition of new nuclei to existing myofiber during hyper-
trophic events has been extensively studied but still the
mechanism leading to satellite cells activation during this
process has not clearly understood. DNA damage experi-
ments induced by c-ray have been used to test the role of
satellite cells in muscle hypertrophy (Rosenblatt et al.
1994; Phelan and Gonyea 1997; Adams et al. 2002).
Compensatory muscle enlargement could be partially pre-
vented following c-irradiation providing a direct evidence
that satellite cells are needed to complete the muscle
increase; nonetheless since the hypertrophic events are not
fully abolished, the possibility of a satellite cells source
surviving, an increased protein synthesis in the remaining
fibers or the effort by other adult muscle stem cells cannot
be excluded (McGeachie and Grounds 1987; Heslop et al.
2000). During mechanical overload or acute/chronic dam-
age the regeneration process activates an inflammatory
response with a consequent release of many growth factors
involved in the remodeling. Such factors like hepatocyte
growth factor (HGF), fibroblast growth factor 6 (FGF6),
interleukin-4 (IL-4), interleukin 6 (IL-6), IGF1 play a key
role during the activation, proliferation and differentiation
events of the satellite cells (Allen et al. 1995; Husmann
et al. 1996; Putman et al. 1999; Horsley et al. 2003).
Among these, IGF1 seems to be the most important factor
linking muscle hypertrophy and satellite cells, muscle
hypertrophy IGF1-dependent is only slightly reduced fol-
lowing c irradiation and prevent the aging-related muscle
wasting thanks to an improved regenerative potential of
satellite cells (Barton-Davis et al. 1999; Musaro et al.
2001). Furthermore, IGF1 increases the DNA content per
myofiber, the centronucleated fiber and the expression of
different myosin isoform; satellite cells isolated from IGF1
overexpressing mice display an increased regenerative
potential compared to wt counterpart, which is mediated by
FoxO1 and the activity of the p27kip1 (Adams and McCue
1998; Chakravarthy et al. 2000; Fiorotto et al. 2003;
Machida et al. 2003). By another part, Notch and IGF1 are
involved in the ageing process of satellite cells with a
consequent loss of muscle weight and physical
performance, in fact manipulations of Notch and IGF1
pathways result in the activation and proliferation of
satellite cells and may provide a good tool to slowdown the
age-related muscle wasting (Conboy and Rando 2002;
Conboy et al. 2003; Sherwood et al. 2004).
microRNA and muscle remodeling
microRNA (miRNA) are small non-coding RNA tran-
scripts, *22 nucleotides long able to inhibit translation or
promote mRNA degradation (common in plants) by
annealing to complementary sequences in the 30untrans-
lated regions (UTR) of specific target mRNA. Individual
miRNA can target dozen of transcripts based of the spec-
ificity of the seed sequence (8 nucleotides) located to the 50
of miRNA. miRNAs can also influenced the expression of
other miRNAs, unraveling an enormous complexity and
regulatory potential for gene expression (Bartel 2004; Stark
et al. 2005; Lee et al. 2007). Recent studies showed another
regulation step in muscle growth and differentiation med-
iated by a collection of muscle specific miRNA, that could
be involved in fine tuning the expression of master genes in
muscle development such as Pax3, MyoD and other cardiac
and skeletal muscle specific factors. Muscle specific dele-
tion of Dicer, a critical component of miRNA machinery,
has deep effect on embryonic and postnatal development,
revealing a key role of miRNAs in controlling muscle
development (O’Rourke et al. 2007). miR-206 is the most
abundant miRNA in adult vertebrate skeletal muscle and
play an important role in muscle plasticity and remodeling.
It has been demonstrated that miRNA206 promotes muscle
differentiation and is strongly upregulated during muscle
hypertrophy induced by surgical removal of gastrocnemius
(synergistic ablation). In this condition the expression level
of pre-miRNA206 is 18-fold higher than the control, with a
correspondent downregulation of miRNA1 and 133, both
involved in skeletal muscle development (McCarthy et al.
2007). Loss of function studies revealed that miRNA206
knockdown through antisense oligonucleotides blocks
myoblasts from exiting the cell cycle inhibiting muscle
differentiation by a negative regulation of the DNA poly-
merase a. Moreover, miRNA206 could interfere with
satellite cells behavior, since among its predicted target
there are cMet and Pax3 essential for satellite cells
migration and early myogenesis steps. This suggests that
regulation of gene expression by this miRNA is crucial for
early and late muscle homeostasis. Nonetheless, a mutation
that causes a dramatic muscle increase in Texel sheep has
been mapped in the myostatin gene, and this mutation
creates a target site for miR-206 and miR-1 resulting in
myostatin downregulation, developing a phenocopy of the
double-muscled cattle previously described in Myostatin
section (Clop et al. 2006). Our knowledge of miRNA
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biology is still in its infancy and future investigation need
to be done for clarifying the molecular mechanism and the
precise involvement of these miRNA in muscle size
control.
Future perspectives
Different molecules are identified so far to interact with
biochemical machinery controlling muscle mass. Several
scientists investigate about the use of small molecules that
interfere with the activity of histone deacetylase and are
now under clinical investigation. The transcriptional
activity of FOXO proteins is negatively regulated by Sir2
overexpression and further studies will address the efficacy
of resveratrol, a Sir2 agonist, in abolishing the atrophic
program driven by FOXO activation (Aziz et al. 2003;
Secrist et al. 2003; Motta et al. 2004; Brunet et al. 2004).
Deacetylase inhibitors, such as valproic acid, represent a
powerful tool in size remodeling and muscle atrophy pre-
vention by mainly activating follistatin expression (Minetti
et al. 2006). Future experiments will determine if these
small drugs could target the progression of muscle wasting
in animal model of cachexia-related diseases. Interestingly,
resveratrol treatment interferes with AKT activity as well
as the other therapeutic approaches to induce muscular
hypertrophy. While addressing the molecular mechanisms
leading to reprogramming will provide new insights into
the factors conferring plasticity to differentiated nuclei, it is
also important to verify these results in more relevant
contexts, such as primary cells and in vivo studies. Magic-
F1 is an HGF-derived molecule with a potential clinical
application as it can induce muscle hypertrophy by acti-
vating MyoD and Myf5, and preventing apoptotic events
(Cassano et al. 2008). Interestingly, no side effects have
been observed in skeletal muscles following electro-
enhanced Magic-F1 DNA transfer or in transgenic mice
expressing Magic-F1 under the control of a muscle-specific
promoter. Magic-F1 is not able to induce the ERK pathway
and this fact is particular relevant to a potential therapeutic
use of this engineered factor. In this regard, the lack of any
mitogenic activity makes Magic-F1 a potentially safe
cytokine for cell therapy. Recently, it has been reported
that HGF gene therapy improves LV remodeling and
dysfunction post-infarction through promotion of cardio-
myocyte hypertrophy, and that HGF plays a role in the
induction of stem cell commitment to the cardiomyocyte
lineage (Fiaccavento et al. 2005; Forte et al. 2006; Li et al.
2003). Magic-F1 exhibits biological effects in the renewal
of skeletal muscles tissues similar though not identical to
those observed for HGF in cardiac tissue regeneration.
Further studies are necessary to elucidate the different
potential effects of HGF in this context and—in this
sense—supplementary studies on Magic-F1 signal trans-
duction could provide useful information. Given the small
size of its cDNA (approximately 1.7 kb), Magic-F1 may be
used alone in a gene therapy setting or inserted as a second
adjuvant transgene in a vector encoding a therapeutic gene
or an anti-cachectic factor (hystone acetylase inhibitor)
(Minetti et al. 2006). Recent works demonstrated the effi-
cacy of pericytic-derived cells, named mesoangioblast,
directly contributing to muscle regeneration in dystrophic
conditions (Sampaolesi et al. 2003, 2006; Galvez et al.
2006; Gargioli et al. 2008). In this context, Magic-F1, as
adjuvant transgene, could positively affect homing ability
and regeneration potential of mesoangioblasts. Finally,
there are evidences indicating that miRNAs may have an
important role in muscle hypertrophy. In fact, miR-1
cluster, miR-133 and miR-206 are involved in muscle
growth and regeneration. The challenge for future studies
will be to better identify the relevant target genes of
muscle-specific miR and how they can be used alone or in
combination with the other molecules or delivered by stem
cells in order to contribute to the improvement of skeletal
muscle growth and strength.
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